AMRN- Amarin mentioned positively at Roth Capital Theflyonthewall.com – 12 hours ago
Roth Capital expects Amarin's AMR101 to receive full FDA approval for the MARINE population and for the company to be bought out, or to sign a major global partnership. Share are Buy rated with a $21 price target.